Do two machine-learning based prognostic signatures for breast cancer capture the same biological processes?

PLoS ONE

Volumn 6, Issue 3, 2011, Pages

  Drier, Yotam ^a   Domany, Eytan ^a  

^a WEIZMANN INSTITUTE OF SCIENCE   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; BREAST CANCER; CELL PROLIFERATION; DNA PACKAGING; DNA REPLICATION; GENE EXPRESSION PROFILING; MACHINE LEARNING; OUTCOME ASSESSMENT; PREDICTION; PROGNOSIS; VALIDATION STUDY; ARTIFICIAL INTELLIGENCE; BIOLOGICAL PHENOMENA AND FUNCTIONS CONCERNING THE ENTIRE ORGANISM; BREAST TUMOR; FEMALE; GENE EXPRESSION REGULATION; GENETICS; HUMAN; PATHOLOGY; STANDARD;

ARTIFICIAL INTELLIGENCE; BIOLOGICAL PROCESSES; BREAST NEOPLASMS; CELL PROLIFERATION; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; PROGNOSIS; REFERENCE STANDARDS;

EID: 79952687473     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0017795     Document Type: Article

References (63)

1. van der Vegt B, de Bock GH, Hollema H, Wesseling J, (2009) Microarray methods to identify factors determining breast cancer progression: potentials, limitations, and challenges. Crit Rev Oncol Hematol 70: 1-11.
2. Dupuy A, Simon RM, (2007) Critical review of published microarray studies for cancer outcome and guidelines on statistical analysis and reporting. J Natl Cancer Inst 99: 147-157.
3. Sotiriou C, Pusztai L, (2009) Gene-expression signatures in breast cancer. N Engl J Med 360: 790-800.
4. Pusztai L, (2009) Gene expression profiling of breast cancer. Breast Cancer Res 11 (Suppl 3): S11.
5. Paik S, Shak S, Tang G, Kim C, Baker J, et al. (2004) A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med 351: 2817-2826.
6. van de Vijver MJ, He YD, van't Veer LJ, Dai H, Hart AA, et al. (2002) A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med 347: 1999-2009.
7. van't Veer LJ, Dai H, van de Vijver MJ, He YD, Hart AA, et al. (2002) Gene expression profiling predicts clinical outcome of breast cancer. Nature 415: 530-536.
8. Buyse M, Loi S, van't Veer L, Viale G, Delorenzi M, et al. (2006) Validation and clinical utility of a 70-gene prognostic signature for women with node-negative breast cancer. J Natl Cancer Inst 98: 1183-1192.
9. de Snoo F, Bender R, Glas A, Rutgers E, (2009) Gene expression profiling: decoding breast cancer. Surg Oncol 18: 366-378.
10. Ein-Dor L, Kela I, Getz G, Givol D, Domany E, (2005) Outcome signature genes in breast cancer: is there a unique set? Bioinformatics 21: 171-178.
11. Michiels S, Koscielny S, Hill C, (2005) Prediction of cancer outcome with microarrays: a multiple random validation strategy. Lancet 365: 488-492.
12. Simon R, (2008) Lost in translation: problems and pitfalls in translating laboratory observations to clinical utility. Eur J Cancer 44: 2707-2713.
13. Ransohoff DF, (2003) Gene-expression signatures in breast cancer. N Engl J Med 348: 1715-1717; author reply 1715-1717.
14. Ein-Dor L, Zuk O, Domany E, (2006) Thousands of samples are needed to generate a robust gene list for predicting outcome in cancer. Proc Natl Acad Sci U S A 103: 5923-5928.
15. Kim SY, (2009) Effects of sample size on robustness and prediction accuracy of a prognostic gene signature. BMC Bioinformatics 10: 147.
16. Taylor JM, Ankerst DP, Andridge RR, (2008) Validation of biomarker-based risk prediction models. Clin Cancer Res 14: 5977-5983.
17. Koscielny S, (2008) Critical review of microarray-based prognostic tests and trials in breast cancer. Curr Opin Obstet Gynecol 20: 47-50.
18. Haibe-Kains B, Desmedt C, Sotiriou C, Bontempi G, (2008) A comparative study of survival models for breast cancer prognostication based on microarray data: does a single gene beat them all? Bioinformatics 24: 2200-2208.
19. Dunkler D, Michiels S, Schemper M, (2007) Gene expression profiling: does it add predictive accuracy to clinical characteristics in cancer prognosis? Eur J Cancer 43: 745-751.
20. Eden P, Ritz C, Rose C, Ferno M, Peterson C, (2004) "Good Old" clinical markers have similar power in breast cancer prognosis as microarray gene expression profilers. Eur J Cancer 40: 1837-1841.
21. Fan C, Oh DS, Wessels L, Weigelt B, Nuyten DS, et al. (2006) Concordance among gene-expression-based predictors for breast cancer. N Engl J Med 355: 560-569.
22. Koscielny S, (2010) Why Most Gene Expression Signatures of Tumors Have Not Been Useful in the Clinic. Science Translational Medicine 2: 14ps12.
23. Chang HY, Sneddon JB, Alizadeh AA, Sood R, West RB, et al. (2004) Gene expression signature of fibroblast serum response predicts human cancer progression: similarities between tumors and wounds. PLoS Biol 2: E7.
24. Miller LD, Smeds J, George J, Vega VB, Vergara L, et al. (2005) An expression signature for p53 status in human breast cancer predicts mutation status, transcriptional effects, and patient survival. Proc Natl Acad Sci U S A 102: 13550-13555.
25. Takahashi S, Moriya T, Ishida T, Shibata H, Sasano H, et al. (2008) Prediction of breast cancer prognosis by gene expression profile of TP53 status. Cancer Sci 99: 324-332.
26. Troester MA, Herschkowitz JI, Oh DS, He X, Hoadley KA, et al. (2006) Gene expression patterns associated with p53 status in breast cancer. BMC Cancer 6: 276.
27. Glinsky GV, Berezovska O, Glinskii AB, (2005) Microarray analysis identifies a death-from-cancer signature predicting therapy failure in patients with multiple types of cancer. J Clin Invest 115: 1503-1521.
28. Paik S, Tang G, Shak S, Kim C, Baker J, et al. (2006) Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer. J Clin Oncol 24: 3726-3734.
29. Chang HY, Nuyten DS, Sneddon JB, Hastie T, Tibshirani R, et al. (2005) Robustness, scalability, and integration of a wound-response gene expression signature in predicting breast cancer survival. Proc Natl Acad Sci U S A 102: 3738-3743.
30. Sotiriou C, Wirapati P, Loi S, Harris A, Fox S, et al. (2006) Gene expression profiling in breast cancer: understanding the molecular basis of histologic grade to improve prognosis. J Natl Cancer Inst 98: 262-272.
31. Sotiriou C, Wirapati P, Loi S, Haibe-Kains B, Desmedt C, et al. (2006) Comprehensive analysis integrating both clinicopathological and gene expression data in more than 1,500 samples: Proliferation captured by gene expression grade index appears to be the strongest prognostic factor in breast cancer (BC). J Clin Oncol (Meeting Abstracts) 24: 507-.
32. Sotiriou C, Piccart MJ, (2007) Taking gene-expression profiling to the clinic: when will molecular signatures become relevant to patient care? Nat Rev Cancer 7: 545-553.
33. Wang Y, Klijn JG, Zhang Y, Sieuwerts AM, Look MP, et al. (2005) Gene-expression profiles to predict distant metastasis of lymph-node-negative primary breast cancer. Lancet 365: 671-679.
34. van't Veer LJ, Bernards R, (2008) Enabling personalized cancer medicine through analysis of gene-expression patterns. Nature 452: 564-570.
35. Radpour R, Barekati Z, Kohler C, Holzgreve W, Zhong XY, (2009) New trends in molecular biomarker discovery for breast cancer. Genet Test Mol Biomarkers 13: 565-571.
36. Sims AH, (2009) Bioinformatics and breast cancer: what can high-throughput genomic approaches actually tell us? J Clin Pathol 62: 879-885.
37. Reyal F, van Vliet MH, Armstrong NJ, Horlings HM, de Visser KE, et al. (2008) A comprehensive analysis of prognostic signatures reveals the high predictive capacity of the proliferation, immune response and RNA splicing modules in breast cancer. Breast Cancer Res 10: R93.
38. Shen R, Chinnaiyan AM, Ghosh D, (2008) Pathway analysis reveals functional convergence of gene expression profiles in breast cancer. BMC Med Genomics 1: 28.
39. Sole X, Bonifaci N, Lopez-Bigas N, Berenguer A, Hernandez P, et al. (2009) Biological convergence of cancer signatures. PLoS One 4: e4544.
40. Yu JX, Sieuwerts AM, Zhang Y, Martens JW, Smid M, et al. (2007) Pathway analysis of gene signatures predicting metastasis of node-negative primary breast cancer. BMC Cancer 7: 182.
41. Clarke R, Ressom HW, Wang A, Xuan J, Liu MC, et al. (2008) The properties of high-dimensional data spaces: implications for exploring gene and protein expression data. Nat Rev Cancer 8: 37-49.
42. Fisher RA, (1970) Statistical methods for research workers Edinburgh Oliver & Boyd pp. xv, 362.
43. Benjamini Y, Hochberg Y, (1995) Controlling the False Discovery Rate: A Practical and Powerful Approach to Multiple Testing. Journal of the Royal Statistical Society Series B (Methodological) 57: 289-300.
44. Bland JM, Altman DG, (1995) Multiple significance tests: the Bonferroni method. Bmj 310: 170.
45. Ashburner M, Ball CA, Blake JA, Botstein D, Butler H, et al. (2000) Gene ontology: tool for the unification of biology. The Gene Ontology Consortium. Nat Genet 25: 25-29.
46. Farcomeni A, (2008) A review of modern multiple hypothesis testing, with particular attention to the false discovery proportion. Stat Methods Med Res 17: 347-388.
47. Rhee SY, Wood V, Dolinski K, Draghici S, (2008) Use and misuse of the gene ontology annotations. Nat Rev Genet 9: 509-515.
48. Tanay A, (2005) Computational Analysis of Transcriptional Programs: Function and Evolution: PhD Thesis, Tel Aviv University.
49. van't Veer LJ, Dai H, van de Vijver MJ, He YD, Hart AA, et al. (2002) Gene expression profiling predicts clinical outcome of breast cancer. Nature 415: 530-536.
50. Chi JT, Wang Z, Nuyten DS, Rodriguez EH, Schaner ME, et al. (2006) Gene expression programs in response to hypoxia: cell type specificity and prognostic significance in human cancers. PLoS Med 3: e47.
51. Teschendorff AE, Miremadi A, Pinder SE, Ellis IO, Caldas C, (2007) An immune response gene expression module identifies a good prognosis subtype in estrogen receptor negative breast cancer. Genome Biol 8: R157.
52. Perou CM, Sorlie T, Eisen MB, van de Rijn M, Jeffrey SS, et al. (2000) Molecular portraits of human breast tumours. Nature 406: 747-752.
53. Altschul SF, Gish W, Miller W, Myers EW, Lipman DJ, (1990) Basic local alignment search tool. J Mol Biol 215: 403-410.
54. Bussey KJ, Kane D, Sunshine M, Narasimhan S, Nishizuka S, et al. (2003) MatchMiner: a tool for batch navigation among gene and gene product identifiers. Genome Biol 4: R27.
55. Barrell D, Dimmer E, Huntley RP, Binns D, O'Donovan C, et al. (2009) The GOA database in 2009-an integrated Gene Ontology Annotation resource. Nucleic Acids Res 37: D396-403.
56. Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, et al. (2005) Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci U S A 102: 15545-15550.
57. Shamir R, Maron-Katz A, Tanay A, Linhart C, Steinfeld I, et al. (2005) EXPANDER-an integrative program suite for microarray data analysis. BMC Bioinformatics 6: 232.
58. Dennis G Jr, Sherman BT, Hosack DA, Yang J, Gao W, et al. (2003) DAVID: Database for Annotation, Visualization, and Integrated Discovery. Genome Biol 4: P3.
59. Huang da W, Sherman BT, Lempicki RA, (2009) Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat Protoc 4: 44-57.
60. Rosty C, Sheffer M, Tsafrir D, Stransky N, Tsafrir I, et al. (2005) Identification of a proliferation gene cluster associated with HPV E6/E7 expression level and viral DNA load in invasive cervical carcinoma. Oncogene 24: 7094-7104.
61. Ross DT, Scherf U, Eisen MB, Perou CM, Rees C, et al. (2000) Systematic variation in gene expression patterns in human cancer cell lines. Nat Genet 24: 227-235.
62. Whitfield ML, George LK, Grant GD, Perou CM, (2006) Common markers of proliferation. Nat Rev Cancer 6: 99-106.
63. Minn AJ, Gupta GP, Padua D, Bos P, Nguyen DX, et al. (2007) Lung metastasis genes couple breast tumor size and metastatic spread. Proc Natl Acad Sci U S A 104: 6740-6745.